TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02460757

Intervention type: OTHER
Intervention: Laryngoscopy
Description: Observation of glottic width in different arms

Intervention type: OTHER
Intervention: Laryngoscopy
Description: Observation of glottic width in different arms

Intervention type: OTHER
Intervention: Laryngoscopy
Description: Observation of glottic width in different arms
Study: NCT02103790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home NIV installation
Study: NCT04570657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI3506
Description: Participants will receive multiple doses of MEDI3506 at dose level 1 or dose level 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI3506
Description: Participants will receive multiple doses of MEDI3506 at dose level 1 or dose level 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive multiple doses of placebo
Study: NCT03689504

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard of care nutrition support
Description: Subjects will be provided with a standard food ration and with a multiple micronutrient powder (Chispitas) or lipid-based nutrient supplement (Nutributter)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care nutrition support
Description: Subjects will be provided with a standard food ration and with a multiple micronutrient powder (Chispitas) or lipid-based nutrient supplement (Nutributter)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based nutrition education
Description: Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
Study: NCT02401646

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polygoni Multiflori Radix complex extract
Description: Intervention is manufactured by Chun-Ho food

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is filled with starch, so does not contain the active ingredient.
Study: NCT00817947

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency chest wall oscillation
Description: Airway clearance using high frequency chest wall oscillation ('The Vest')
Study: NCT03845413

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Schedule an appointment to attend tobacco cessation at Basic Health Unit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program
Description: 12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program
Study: NCT01917968

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uphold Lightweight Vaginal Support System
Description: Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional native tissue repair
Description: Sarcrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy
Study: NCT01434576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HGS1025
Description: 2 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HGS1025
Description: 10 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by IV infusion on Day 0, 14, 28 and 56. Subjects receiving placebo during the first 8 weeks of treatment will be given the option to receive HGS1025 10 mg/kg in the continuation phase of the study.
Study: NCT04440449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle App
Description: A mobile app used to assist with lifestyle changes

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle App
Description: A mobile app used to assist with lifestyle changes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Look AHEAD behavior lifestyle intervention
Description: A modified Look AHEAD behavior lifestyle intervention with smartphone-based self-monitoring of diet and physical activity

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Abbreviated Look AHEAD behavior lifestyle intervention
Description: An abbreviated Look AHEAD behavior lifestyle intervention with smartphone-based self-monitoring of diet and physical activity
Study: NCT01351350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel intravenous infusion
Study: NCT01781988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin, gemcitabine , pametrexed
Description: A.individual therapy :enrolled patients with ERCC1 negative tumors who received carboplatin and a third-generation agent (gemcitabine or pametrexed) based on RRM1 or TS expression. If RRM1 protein was negatively expressed in the tumor tissues, gemcitabine was used, whereas pemetrexed was used if RRM1 was positively expressed and TS was negatively expressed.~B.non-individualized therapy :enrolled patients who received carboplatin and a third-generation agent but were not based on ERCC1, RRM1, or TS expression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin, gemcitabine , pametrexed
Description: A.individual therapy :enrolled patients with ERCC1 negative tumors who received carboplatin and a third-generation agent (gemcitabine or pametrexed) based on RRM1 or TS expression. If RRM1 protein was negatively expressed in the tumor tissues, gemcitabine was used, whereas pemetrexed was used if RRM1 was positively expressed and TS was negatively expressed.~B.non-individualized therapy :enrolled patients who received carboplatin and a third-generation agent but were not based on ERCC1, RRM1, or TS expression.
Study: NCT01209767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryolipolysis
Description: During cryolipolysis, the system drew fat tissue into an applicator then exposed the extracted fat tissue to cold temperatures. The cold exposure caused fat cells to die, with the goal to decrease the raised areas of cellulite

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcision
Description: Subcision was performed by inserting a specially designed needle under the skin after local numbing medication is injected. The needle is moved in a repetitive motion parallel to the skin to separate the surface tissue from the deeper scar tissue with the goal to improve the dimpling caused by these tissues sticking together.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study: NCT01351350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: trastuzumab intravenous infusion
Study: NCT00400686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epoetin alfa
Description: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.
Study: NCT03580044

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ATM-AVI
Description: ATM-AVI doses (loading, extended loading and maintenance) and the dosing frequency of the maintenance dose are dependent on renal function. Subjects will be given a loading dose of 500 mg ATM plus 167 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 30 minutes. This treatment will immediately be followed by an extended loading dose of 1500 mg ATM plus 500 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 3 hours. Then there will be a 3 hour or 5 hour gap. Subjects will receive a maintenance dose of 1500 mg ATM plus 500 mg AVI every 6 hours or 750 mg ATM plus 250 mg AVI every 6 hours, or 675 mg ATM plus 225 mg AVI every 8 hours. Subjects with cIAI will also receive Metronidazole (MTZ) 500 mg IV q8h over 60 minutes. The first dose of MTZ will be started immediately after the extended loading dose of ATM-AVI has completed and treatment will be continued until the end of the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT
Description: The comparator treatment in this study is best available therapy (BAT) based upon site practice and local epidemiology. The choice of BAT (monotherapy or combination) for each subject must be recorded prior to randomization. If the chosen BAT does not provide adequate anaerobic coverage for cIAI subjects MTZ is to be administered as a co therapy. BAT dose, frequency, dose adjustments with renal impairment will be based on per local package inserts.
Study: NCT01365754

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard
Description: fusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: new
Description: dynamic stabilization
Study: NCT00481936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB6-845
Description: Intravenous infusion once weekly for 4 weeks
Study: NCT03531255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: Complement (C3) Inhibitor
Study: NCT01321411

Intervention type: OTHER
Intervention: Near Infrared Spectroscopy
Description: Healthy Volunteers:~Study #1 (Abnormal Pulmonary Resistance) subjects will breathe through a Starling resistor simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV.~Study #2 (Abnormal Pulmonary Compliance) subjects will breathe while wearing a chest binder simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV.

Intervention type: OTHER
Intervention: Near Infrared Spectroscopy
Description: Clinical Volunteers:~Study #3 (Abnormal Pulmonary Resistance) subjects recovering from COPD exacerbations will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB.~Study #4 (Abnormal Pulmonary Compliance) subjects recovering from ARDS will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB.
Study: NCT01010464

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adhesion Reduction Plan
Description: Lysis of adhesions and application of a minimum of 4 sheets of a sodium hyaluronate-based bioresorbable membrane
Study: NCT02988908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Participants received donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14
Study: NCT03985202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured exercise programme
Description: 9 week structured exercise programme. 3 sessions per week. (Intervention).The patient will be invited to the hospital for a 45-minute exercise counselling session, incorporating behaviour modification techniques. These behaviour modification techniques will be reinforced during the supervised exercise sessions. Participants will be offered 3 sessions of supervised aerobic interval exercise sessions per week on a cycle ergometer for 9 weeks.Exercise programmes will be tailored to each patient, taking previous level of activity, mobility and any barriers to exercise into consideration.
Study: NCT04035291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercises,play therapy models and positioning, handling and holding principles for babies, daily routins

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: exercises,play therapy models and positioning, handling and holding principles for babies, daily routins
Study: NCT02847312

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High avenanthramide, phenolic acid
Description: High avenanthramide and high phenolic acid, matched with energy and insoluable fibre.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low avenanthramide, medium phenolic acid
Description: Low avenanthramide and moderate phenolic acid, matched with energy and insoluable fibre.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control are matched with energy and insoluable fibre.
Study: NCT02353988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Patients in experimental group are designated to take bicalutamide orally, 150mg on a continuous schedule. The investigator should pay attention to the patients' adverse event. Every month, the patients will be evaluated for the adverse event by the criterion National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0. Every 2 months, the patients will be evaluated for the clinical effects. If disease progressed, the patients would be ruled out.~Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance. A maximum of 2 dose reductions for grade \>= 3 toxicity were allowed (100 and 50 mg). A maximum of 2 weeks was permitted for treatment delays due to toxicity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physician's Choice
Description: The comparator group, treatment of physician's choice (TPC), represented a mix of agents (both approved and non-approved for metastatic breast cancer) to mirror clinical practice at the time in this setting.~The 60 patients are enrolled in the study, before randomized to the two arms, each of them will be assessed for eligibility and then their proposed TPC.~Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance.
Study: NCT02302300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manufacturer STELLAR 150
Description: 5 days of non-invasive ventilation at two levels of pressure from it pre-operative, followed by 5 days in post-operative.
Study: NCT03123172

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: arterial and central venous blood gases
Description: withdrawal of arterial and central venous blood gases to measure Co2 gap
Study: NCT02667808

Intervention type: OTHER
Intervention: Focus Group
Description: Subjects will participate in four to eight group discussions aimed to evaluate fertility intentions, family planning, and sexual health behaviors. Discussions will be 1-2 hours in length. Groups will be conducted among men and women.

Intervention type: OTHER
Intervention: Questionnaire
Description: Participants will complete a questionnaire assessing reproductive health knowledge, attitudes and practices related to family planning, and fertility and sexual health. The questionnaire will take no longer than 30 minutes to complete.
Study: NCT04390958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 125mg/m2 ivgtt d1、d8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60mg/m2 ivgtt d1 or d1-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1750mg/m2 po bid d1-14
Study: NCT02061930

Intervention type: PROCEDURE
Intervention: single crowns supported by implants
Description: The implant placement procedures were planned based on clinical and radiographic evaluation. During the surgeries, the mid-crestal incision and intra-crevicular incision were made following local articaine infiltration anesthesia. No releasing incisions were made. After full-thickness flaps were elevated labially and lingually to expose the alveolar ridge, the implants were placed according to the standard surgical procedures defined by the manufacturer. After a healing time of 10-16 weeks, implant-level impressions were taken. The porcelain (Ivoclar-Vivadent AG, Schaan, Lichtenstein) fused to noble metal crowns were fabricated. Abutment screws were torqued to 15 Ncm. Crowns were cemented with HY-bond Glassionomer Cement
Study: NCT04466904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: Administrated by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: Administrated by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: Administrated by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administrated by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administrated by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administrated by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administrated by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administrated by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administrated by subcutaneous injection
Study: NCT03160781

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Combination of Intraosseous and Intraarticular Infiltration of Platelet Rich Plasma
Study: NCT02346006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: More physical activity.
Description: Subjects receiving more physical activity in school.
Study: NCT02950948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone will be administered subcutaneously once a day for 14 days/month, for 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo solution will be administered subcutaneously once a day for 14 days/month, for 12 months.
Study: NCT02441036

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultherapy Treatment
Description: Focused ultrasound energy delivered below the surface of the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultherapy Treatment
Description: Focused ultrasound energy delivered below the surface of the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultherapy Treatment
Description: Focused ultrasound energy delivered below the surface of the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultherapy Treatment
Description: Focused ultrasound energy delivered below the surface of the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultherapy Treatment
Description: Focused ultrasound energy delivered below the surface of the skin.
Study: NCT01948999

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ECT
Description: Electroconvulsive Therapy inclusive anesthesia and concomitant muscular paralysis

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: SHAM ECT
Description: Anesthesia and concomitant muscular paralysis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia
Description: Temporary induced state of analgesia

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Anesthesia
Description: Temporary induced state of analgesia
Study: NCT04010955

Intervention type: DRUG
Intervention: Edoxaban Monotherapy
Description: when the patients will be initially registered in this study, duty physicians will make a decision to give additional antiplatelet therapy in addition to standard edoxaban therapy.

Intervention type: DRUG
Intervention: Edoxaban Monotherapy
Description: when the patients will be initially registered in this study, duty physicians will make a decision to give additional antiplatelet therapy in addition to standard edoxaban therapy.
Study: NCT03335969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: colon irrigation
Description: Study is to compare bowel movement patterns before and after colon irrigation.